SIADHMANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

690 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Euglycemic DKA (SGLT2 inhibitor)Galactosemia GLP-1 receptor agonist complications (retained gastric contents, aspiration risk)Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Insulin pump failure Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp49

Immediate priorities

›Severe hyponatremia with neurological compromise

›Seizure or coma from cerebral edema

›Most dangerous presentation requiring immediate intervention

›Risk of cerebral herniation if uncorrected

›Serum sodium <120 mmol/l regardless of symptoms

›Hospitalization mandated

›Continuous monitoring required

›Acute hyponatremia onset <48 hours

›Higher risk of cerebral edema than chronic

›Rapid correction better tolerated than in chronic SIADH

›If seizures or coma, give 3% hypertonic saline 100-150 mL IV bolus immediately

›Repeat up to 2-3 times as needed

›Target raise serum Na by 4-6 mmol/l within 1-2 hours

Hemodynamic and monitoring targets

›Monitoring bundle for severe hyponatremia

›Serum sodium every 2-4 hours during active correction

›Target correction rate <10 mmol/l in first 24 hours

›Target correction rate <18 mmol/l in 48 hours

›Neurological status at frequent intervals

›GCS trend

›Seizure detection

›Urine output monitoring

›Spot urine sodium and osmolality

›Aquaresis response tracking

›Correction rate limits

›Standard patients: max 10 mmol/l per 24 hours

›ODS prevention threshold

02History/hx66

Onset and symptom severity

›Tempo of hyponatremia

›Acute onset <48 hours

›Higher risk of cerebral edema

›Symptoms may be more severe for degree of sodium drop

›Chronic onset >=48 hours

›Brain adaptation reduces symptoms

›Higher ODS risk with rapid correction

›Symptom severity by sodium level

›Mild symptoms: Na 130-134 mmol/l

›Weakness, headache, cognitive slowing

›Often asymptomatic or subtle

›Moderate symptoms: Na 125-129 mmol/l

›Nausea, confusion, gait instability

›Falls risk

›Severe symptoms: Na <125 mmol/l

›Vomiting, somnolence, seizures, coma

›Risk of respiratory arrest

Medication and exposure history

›SIADH-causing medications

›SSRIs: up to 32% incidence especially in older underweight women

›Mirtazapine lowest risk among antidepressants

›Onset typically within weeks of starting

›Carbamazepine and oxcarbazepine

›Direct AVP-like effect

›Dose-dependent

›Other causative agents

›Opiates, cyclophosphamide, vincristine, platinum compounds

03Physical Exam/exam50

Volume status assessment

›Euvolemia expected in SIADH

›No peripheral edema

›Edema suggests hypervolemic hyponatremia

›Heart failure or cirrhosis consideration

›No orthostatic hypotension

›Orthostasis suggests hypovolemic hyponatremia

›Adrenal insufficiency consideration

›Jugular venous pressure

›Flat JVP suggests volume depletion

›Elevated JVP suggests hypervolemia

›Mucous membranes and skin

›Dry mucosa and poor skin turgor suggest hypovolemia

›May indicate thiazide-induced or GI-loss hyponatremia

›Not SIADH

›Normal skin turgor in SIADH

Neurological exam

›Mental status assessment

›GCS score

›GCS <13 indicates severe brain dysfunction

›Escalation to acute resuscitation indicated

›Orientation and cognition

›Confusion and disorientation suggest moderate to severe hyponatremia

›Subtle cognitive changes in mild hyponatremia often missed

›Gait testing

›Ataxia even with Na 130-134 mmol/l

›Falls risk assessment

›Focal neurological signs

04Differential Diagnosis/ddx50

Euvolemic hyponatremia

›SIADH (ICD-10 E22.2)

›Most common cause of euvolemic hypotonic hyponatremia

›>15% of hospitalized patients affected

›Diagnosis of exclusion

›Serum osmolality <275 mOsm/kg with urine osmolality >100 mOsm/kg

›Urine sodium typically >30 mmol/l

›Euvolemic clinical state

›Adrenal insufficiency (ICD-10 E27.1)

›Secondary adrenal insufficiency most common mimic of SIADH

›Hypopituitarism: cortisol deficiency increases AVP sensitivity

›May have identical lab pattern to SIADH

›Cortisol level and ACTH stimulation test mandatory before diagnosing SIADH

›Failure to exclude is a critical pitfall

›Severe hypothyroidism (ICD-10 E03.9)

›Rare cause of euvolemic hyponatremia

›TSH required to exclude

›Mechanism: reduced cardiac output and GFR

Hypovolemic hyponatremia

›Thiazide-induced hyponatremia

›Hypovolemic mechanism: not SIADH

›Responds to saline challenge

›Urine sodium >30 mmol/l can be confusing

›Discontinue thiazide; saline replacement

›GI losses and third spacing

›Vomiting, diarrhea, burns

›Clinical hypovolemia present

›Urine sodium typically <20 mmol/l

05Laboratory Tests/lt51

Core diagnostic workup

›Serum electrolytes and osmolality

›Serum sodium: defines severity and guides correction rate

›Na <120 mmol/l: mandates hospitalization

›Na 120-129 mmol/l: moderate, close monitoring

›Na 130-134 mmol/l: mild, often asymptomatic

›Serum osmolality

›Must be <275 mOsm/kg for hypotonic hyponatremia diagnosis

›Pseudohyponatremia excluded if osmolality truly low

›Potassium

›Hypokalemia amplifies ODS risk

›Correct concurrent hypokalemia aggressively

Urine diagnostics

›Urine osmolality

›Inappropriately concentrated urine >100 mOsm/kg diagnostic requirement

›Typically >300 mOsm/kg in SIADH

›<100 mOsm/kg suggests primary polydipsia or beer potomania

›Urine sodium

›>30 mmol/l (often >40 mmol/l) supports SIADH

›<20 mmol/l suggests hypovolemic hyponatremia

›Can be elevated with thiazides: use clinical context

›Fractional excretion of urate (FEUrate)

›Elevated >12% in SIADH improves diagnostic accuracy to ~95%

›Remains elevated even after sodium correction

›Distinguishes SIADH from hypovolemic hyponatremia where FEUrate normalizes

Exclusion labs

›Cortisol and ACTH stimulation test

›Random cortisol <275 nmol/l warrants stimulation test

06Diagnostic Tests/dt82

Scoring Systems

›SIADH diagnostic criteria (Bartter and Schwartz criteria)

›Serum osmolality <275 mOsm/kg

›Hypotonic state confirmed

›Urine osmolality >100 mOsm/kg during hypotonicity

›Inappropriate urinary concentration

›Clinical euvolemia

›No signs of hypovolemia or hypervolemia

›Urine sodium >30 mmol/l with normal dietary sodium intake

›Excludes hypovolemia

›Normal adrenal and thyroid function

›Exclusionary requirements

›Hyponatremia severity classification

›Mild: Na 130-134 mmol/l

›Non-emergent management

›Moderate: Na 125-129 mmol/l

›Urgent evaluation

›Severe: Na <125 mmol/l

›Emergency management

›ODS risk scoring

›High-risk features for osmotic demyelination

›Serum sodium <105 mmol/l

›Alcohol use disorder

›Malnutrition

›Hypokalemia

›Liver disease

›Limit correction to 8 mmol/l per 24 hours in high-risk patients

MRI

›MRI brain for osmotic demyelination syndrome

›Indication: biphasic neurological deterioration after sodium correction

›Initial improvement followed by new deficits 2-7 days later

›Pontine and extrapontine demyelination pattern

›Findings in ODS

›Central pontine myelinolysis: T2/FLAIR hyperintensity in pons

›Extrapontine demyelination in basal ganglia, thalamus

›Timing of MRI findings

›May be normal initially; delayed repeat imaging

›DWI sequences most sensitive early

›MRI brain for underlying cause

›Suspected CNS mass lesion causing SIADH

›Pituitary adenoma or hypothalamic lesion

›Brain metastasis

›Limbic encephalitis evaluation

›Anti-LGI1 antibody encephalitis: 60-90% associated with SIADH

›T2/FLAIR signal in hippocampi and temporal lobes

›CT chest

›Indications

›New SIADH without obvious cause

›Malignancy screening in older or smoking patients

›Findings relevant to SIADH

›Small-cell lung cancer: central mass with mediastinal adenopathy

›Pneumonia: consolidation in dependent segments

›TB: upper lobe cavitation or miliary pattern

›CT head

›Indications

›Focal neurological deficits with hyponatremia

›Suspected SAH or intracranial mass

›Altered mental status without clear metabolic cause

›Findings

›SAH: hyperdense subarachnoid cisterns

›Mass lesion: ring-enhancing or expansile lesion

›Cerebral edema: sulcal effacement and narrow ventricles

›CT abdomen and pelvis

›Occult malignancy screening in idiopathic SIADH

›Particularly older patients

›GI and GU primary cancers

›Head and neck cancers: separate CT neck with contrast

Ultrasound

›Renal ultrasound

›CKD assessment in chronic hyponatremia

›Small echogenic kidneys suggest CKD

›Relevant for medication dosing

›Liver and ascites assessment

›Cirrhosis evaluation when suspected

›Nodular liver surface and splenomegaly

›Ascites: hypervolemic hyponatremia

›Cardiac echocardiography

›Heart failure exclusion

›Reduced ejection fraction or diastolic dysfunction

›Bilateral pleural effusions and dilated IVC

›POCUS for volume status

›IVC collapsibility index

›Collapsed IVC: hypovolemia supports alternate diagnosis

›Distended IVC: hypervolemia

›Limited by operator dependency and patient body habitus

07Disposition/dispo53

Admission indications

›Mandatory admission criteria

›Serum sodium <120 mmol/l regardless of symptoms

›Class I level of care requirement

›IV access and continuous monitoring

›Severe neurological symptoms

›Seizures, coma, somnolence

›ICU-level care indicated

›Acute hyponatremia with moderate to severe symptoms

›High-risk postoperative or exercise-associated cases

›Risk of rapid progression

›Additional admission triggers

›Initiation of tolvaptan therapy

›Requires inpatient sodium monitoring every 6-8 hours

›Overcorrection occurs in 13-25% in real-world use

›Intracranial pathology with any hyponatremia

›SAH: cerebral salt wasting or SIADH coexist

›Fluid restriction contraindicated in SAH

›Underlying cause requiring hospitalization

›Pneumonia

›New malignancy identification

Level of care selection

›ICU indications

›Active seizures or coma

›Airway protection risk

›Hypertonic saline infusion requiring close monitoring

›Na <115 mmol/l

›Severe cerebral edema risk

08Treatment/t84

Emergency treatment: severe symptomatic hyponatremia

›Hypertonic saline 3% for seizures, coma, or severe neurological compromise

›Initial dose: 100-150 mL IV bolus over 10-20 minutes

›Repeat up to 2-3 times as needed

›Target: raise serum Na by 4-6 mmol/l within 1-2 hours

›Correction limits

›Max 10 mmol/l in first 24 hours: standard patients

›Max 8 mmol/l in 24 hours: high ODS risk patients

›Max 18 mmol/l in 48 hours total

›Preparation: 3% NaCl available in pre-mixed bags or mixed as 30 mL 23.4% NaCl in 470 mL NS

›Peripheral or central IV acceptable

›Dedicated IV line preferred

First-line non-emergency treatment

›Address underlying cause

›Discontinue offending medications

›SSRIs, carbamazepine, NSAIDs, opiates

›Sodium typically improves within days of stopping causative drug

›Treat underlying infection

›Antibiotics for pneumonia

›Sodium normalizes with resolution

›Manage malignancy

›Tumor treatment reduces ectopic AVP production

›Oncology referral for definitive management

›Fluid restriction: first-line long-term management

›Moderate restriction: <1.5 L/day for mild SIADH

›Includes all fluid sources

›Patient education essential for adherence

›Severe restriction: <1 L/day for more refractory cases

›Approximately 50% of patients fail fluid restriction alone

›Urine-to-serum electrolyte ratio guides restriction intensity

›Urine osmolality-guided restriction

›If urine osm/serum osm ratio >1, restriction <500 mL/day needed

›Ratio <1: restriction more effective

Second-line pharmacological treatment

›Oral urea: effective and inexpensive option

›Dose: 15-60 g/day divided doses

›30 g promotes approximately 1 L free water excretion per day

›Dissolve in fruit juice for palatability

›Mechanism: osmotic diuresis promotes aquaresis

›Increases solute load and urinary water loss

›Safe in liver disease unlike tolvaptan

›Monitoring: BUN elevation expected and not harmful

›Serum sodium check weekly until stable

›NaCl tablets plus furosemide

›NaCl tablets: 2-5 g/day in divided doses

›Increases solute delivery to kidney

›Promotes free water excretion

›Furosemide: 20 mg twice daily

›Blunts urinary concentrating ability

›Avoid in hypertension or heart failure

›Combined effect: augmented aquaresis

›Practical and inexpensive

›Potassium monitoring required with furosemide

Vaptans

›Tolvaptan: V2 receptor antagonist

›Initiating dose: 7.5-15 mg/day orally

›Initiate in hospital with sodium monitoring every 6-8 hours

›Overcorrection occurs in 13-25% in real-world practice

›Uptitration

›Increase to 30 mg/day if insufficient response after 24 hours

›Maximum 60 mg/day

›Contraindications

›Liver disease: FDA black box warning; hepatotoxicity risk

›Use >30 days: FDA warning due to liver toxicity

›Concurrent hypertonic saline: risk of overcorrection

›Volume depletion

›Monitoring

›Serum sodium every 6-8 hours first 24 hours

›Liver function tests at baseline and during treatment

›SALT trials: sodium correction of 4.0-6.2 mmol/l over first 24 hours

›Class IIb recommendation for chronic euvolemic hyponatremia

Emerging and adjunct therapies

›Empagliflozin (SGLT2 inhibitor)

›Promotes osmotic diuresis via glucosuria

›Limited but promising data in SIADH

›Not yet standard of care

›Mechanism differs from vaptans

›Glucose-driven aquaresis

›Renal tubular effect

›Demeclocycline: largely replaced by vaptans

›Mechanism: partial nephrogenic diabetes insipidus induction

›Slow onset 3-5 days

›Nephrotoxicity and photosensitivity limit use

›Not recommended as first or second line

›Dietary solute augmentation

›Salt and protein intake increase (~1 g/kg/day protein)

›Promotes osmotic diuresis

›Sodium-rich broth and salt tablets

›Avoid excessive free water intake

09Special Populations/sp73

Pregnancy

›Physiologic changes affecting SIADH in pregnancy

›Serum osmolality normally lower in pregnancy by 5-10 mOsm/kg

›Lower threshold for AVP release reset

›Define SIADH relative to pregnancy norms

›Oxytocin used in labor has antidiuretic properties

›Risk of acute hyponatremia if hypotonic IV fluids given concurrently

›Prefer isotonic fluids for labor hydration

›Treatment modifications in pregnancy

›Tolvaptan: avoid in pregnancy

›No safety data; teratogenicity concern in animal studies

›Demeclocycline: contraindicated in pregnancy

›Fluid restriction: acceptable in pregnancy

›Monitor fetal wellbeing with severe restriction

›Oral urea: limited data; use with caution

›Hypertonic saline for severe symptomatic hyponatremia

›Life-threatening maternal hyponatremia: maternal life takes priority

›Fetal monitoring during treatment

›Fetal considerations

›Severe maternal hyponatremia affects fetal brain

›Rapid correction of maternal sodium improves fetal status

›Obstetrics consultation mandatory

Geriatric

›Epidemiology in older adults

›Idiopathic SIADH most common in elderly

›Age-related decline in renal diluting capacity

›Polypharmacy and multiple comorbidities

›SSRI-induced SIADH: highest risk in older underweight women

›Occurs within weeks of initiation or dose change

›SSRIs account for significant proportion of drug-induced cases

›Atypical presentations

›Cognitive decline and falls at Na 130-134 mmol/l

›Often attributed to baseline dementia

›Sodium check essential in unexplained functional decline

›Chronic hyponatremia: even mild levels increase fracture risk

›Falls from gait instability

›Bone density effects of chronic low sodium

›Treatment considerations

›Fluid restriction compliance may be difficult

›Cognitive impairment limits self-management

›Caregiver education essential

›Oral urea preferred second-line over tolvaptan in elderly

›Lower risk of overcorrection

›Renal function monitoring required

›ODS risk higher in elderly with multiple risk factors

›Malnutrition common

›Alcohol use disorder may be under-recognized

Pediatrics

›Epidemiology and common causes in children

›Postoperative hyponatremia: most common pediatric scenario

›Hypotonic maintenance fluids historically a major cause

›Now largely preventable with isotonic maintenance fluids

›CNS pathology: meningitis, encephalitis, head trauma

›SAH rare but SIADH risk similar to adults

›MDMA ingestion in adolescents

›Acute severe hyponatremia risk

›Coupled with excessive water intake at events

›Clinical differences from adults

›Children more susceptible to cerebral edema

›Smaller cranial vault relative to brain volume

›Rapid deterioration possible

›Symptoms more likely to include vomiting and seizures

›Even at Na 125-130 mmol/l

›Treatment in children

›Hypertonic saline 3% for severe symptomatic hyponatremia

›2 mL/kg IV bolus over 5-10 minutes

›Repeat once if no improvement after 30 minutes

›Target raise sodium by 4-6 mmol/l within 1-2 hours

›Fluid restriction rate weight-based

›Restrict to insensible losses plus urine output

›Tolvaptan: not approved for children under 18

›Limited pediatric safety data

›Avoid routine use

›Correction rate limits same as adults

›Max 10 mmol/l in first 24 hours

›Closer monitoring recommended given susceptibility

10Background/b74

Epidemiology

›Prevalence and burden

›Most frequent cause of hypotonic hyponatremia

›>15% of hospitalized patients affected

›Hyponatremia affects ~35% of all inpatients overall

›Idiopathic in 17-60% of cases

›Occult malignancy identified later in subset

›Thorough initial workup reduces idiopathic classification

›Associated conditions prevalence

›CNS pathology

›SAH: SIADH in up to 56% of cases

›Transsphenoidal surgery: SIADH in up to 35%

›Anti-LGI1 limbic encephalitis: 60-90% association

›Malignancy

›Small-cell lung cancer: ~25% of cancer-related SIADH

›Overall cancer association common reason for investigation

›Drug-induced

›SSRIs: up to 32% incidence in susceptible groups

›Most common reversible cause

›Mortality and morbidity

›Chronic mild hyponatremia increases falls risk

›Fracture risk elevated

›Mortality association in hospitalized patients

›Severe acute hyponatremia: brain herniation and death possible

›Osmotic demyelination syndrome: serious complication of overcorrection

Pathophysiology

›AVP-mediated water retention

›Nonosmotic release of arginine vasopressin (AVP)

›Normal: AVP released only when serum osmolality >280 mOsm/kg

›SIADH: AVP released independently of osmolality

›AVP binds V2 receptors in renal collecting duct

›Aquaporin-2 water channels inserted into apical membrane

›Free water reabsorption leads to dilutional hyponatremia

›Result: hypotonic plasma with concentrated urine

›Euvolemia maintained by natriuresis as volume expands

›Aldosterone suppressed; urine sodium appropriately high

›Cerebral edema mechanism

›Acute hyponatremia: osmotic water movement into brain cells

›Cellular swelling and intracranial pressure rise

›Herniation possible with severe acute drop

›Chronic adaptation: brain extrudes osmolytes

›Taurine, glutamate, potassium loss from brain cells

›Reduces cerebral edema at expense of ODS vulnerability

›ODS mechanism

›Rapid correction of chronic hyponatremia reverses brain adaptation

›Sudden increase in extracellular osmolality

›Brain shrinkage damages myelin in metabolically vulnerable areas

›Pons most vulnerable due to vascular supply and white matter density

›Extrapontine areas also affected in severe cases

Therapeutic Considerations

›Correction rate principles

›Under-correction in severe acute hyponatremia leads to continued cerebral edema

›Emergent correction of 4-6 mmol/l in first 1-2 hours is safe and lifesaving

›Class I consensus recommendation for severe symptomatic cases

›Over-correction in chronic hyponatremia causes ODS

›Limit total correction to 10 mmol/l per 24 hours standard patients

›8 mmol/l per 24 hours high-risk patients

›Desmopressin clamping strategy

›Scheduled desmopressin 2-4 mcg IV every 6-8 hours prevents uncontrolled aquaresis

›Allows controlled sodium rise with predictable correction

›Treatment selection rationale

›Fluid restriction fails in ~50% of patients

›High urine-to-plasma electrolyte ratio predicts failure

›Second-line needed when restriction insufficient

›Oral urea vs tolvaptan

›Urea: cheaper, no liver contraindication, long track record

›Tolvaptan: faster and more predictable correction; liver risk limits long-term use

›Isotonic saline contraindicated in SIADH

›Urinary electrolyte concentration exceeds infused sodium concentration

›Saline worsens hyponatremia in SIADH

›Chronic SIADH management principles

›Identify and treat cause if reversible

›Drug-induced: stop offending agent

›Malignancy-related: treat primary tumor

›Long-term fluid restriction requires ongoing patient education

›Adherence tracking with periodic sodium checks

›Dietary sodium and protein optimization

11Patient Discharge Instructions/pdi34

copy discharge instructions

›SIADH and low sodium home care

›Fluid restriction is your most important treatment

›Drink no more than the amount specified by your doctor

›Count all fluids: water, juice, coffee, soup, ice cream

›Follow a higher-salt and higher-protein diet if advised

›Salt tablets or sodium-rich broth as recommended

›Protein goal approximately 1 gram per kg body weight per day

›Take all medications exactly as prescribed

›If a medication was stopped because it caused low sodium, do not restart it without talking to your doctor

›Avoid excessive free water intake

›Do not drink large amounts of water at once

›Avoid energy drinks or sports drinks with low sodium

›Warning signs to return to ER immediately

›Confusion or difficulty speaking

›Difficulty walking or new unsteadiness

›Severe headache

›Seizure or shaking episode

›Persistent vomiting preventing fluid restriction

›Extreme drowsiness or difficulty staying awake

›If a family member notices you are unusually confused

›Follow-up plan

›Blood sodium recheck within 1-3 days of discharge

›Earlier if symptoms change

›Your doctor will tell you when and where

›Clinic or specialist follow-up as arranged

›Nephrology, endocrinology, or internal medicine

›If on new medications for sodium, do not stop without calling your doctor

12References/r24

Guidelines and key sources

›Primary references

›Adrogué HJ, Madias NE. The Syndrome of Inappropriate Antidiuresis. NEJM 2023

›Comprehensive management algorithm and correction rate evidence

›NEJM doi/10.1056/NEJMcp2210411

›Adrogué HJ, Tucker BM, Madias NE. Diagnosis and Management of Hyponatremia: A Review. JAMA 2022

›Differential diagnosis framework and diagnostic criteria

›JAMA doi/10.1001/jama.2022.11176

›Warren AM, Grossmann M, Christ-Crain M, Russell N. Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management. Endocrine Reviews 2023

›ODS risk stratification and management evidence

›PubMed 36974717

›Supporting evidence

›Beck J. Treatment of Chronic Hyponatremia and Controversy About Osmotic Demyelination Syndrome. Best Pract Res Clin Endocrinol Metab 2025

›ODS controversy and treatment thresholds

›PubMed 41219109

›Refardt J, Winzeler B, Christ-Crain M. Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis. Clin Endocrinol 2019

›Copeptin as AVP surrogate in diagnosis

›Wiley doi/10.1111/cen.13991

›Miller NE, Rushlow D, Stacey SK. Diagnosis and Management of Sodium Disorders. Am Fam Physician 2023

›Primary care perspective on hyponatremia management

›PubMed 37983699

›Coding standards

›ICD-10 E22.2: syndrome of inappropriate antidiuretic hormone secretion

›ICD-10 E87.1: hyponatremia

›SNOMED CT: syndrome of inappropriate antidiuretic hormone secretion disorder concept

Learn More: SIADH→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.